ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 310

STAT3 Plays a Central Role in NLRP3 Inflammasome-Mediated IL-1β Production and Pyronecrosis

Jehad H. Edwan1, Tri M. Tran2, Mones Abu-Asab3, Raphaela T. Goldbach-Mansky4 and Robert A. Colbert1, 1NIAMS NIH, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD, 3NEI NIH, Bethesda, MD, 4Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Inflammation, interleukins (IL), Janus kinase (JAK), nod-like receptor (NLR) and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Gain of function mutations in NLRP3 cause cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID), which is characterized by recurrent episodes of systemic and organ-specific inflammation. Mutations in NLRP3 result in self-activation, promoting inflammasome-mediated IL-1beta processing and release, and can induce cell death through a process known as pyronecrosis. Many inflammatory disease manifestations are responsive to IL-1beta inhibitors, although patients often continue to have minor disease flares in the context of infections or other stressors. The hematopoietic cells that are the major producers of IL-1beta in NOMID and mechanisms mediating IL-1beta release and pyronecrosis have not been well elucidated.

Methods: Whole blood cells from NOMID patients and controls, THP-1 monocytic cells, and stably STAT3 knock down THP-1 cells were stimulated with LPS in the presence of cathepsin B and STAT3 inhibitors, followed by ATP treatment. Supernatants were collected and incubated with IL-1beta capturing beads. Cells were fixed and permeabilized and stained with IL-1beta, CD14, CD16 and CD83 antibodies, and cells and beads were evaluated by flowcytometry. LPS stimulated cells were also evaluated using immunofluorescent and electron microscopy and western blot assays.

Results: A sub-population of monocytes characterized by CD14hi/CD16low expression, produce the majority of IL-1beta in peripheral blood in response to LPS stimulation in NOMID and control PBMCs. In NOMID patients this subpopulation of monocytes also undergoes rapid cell death following LPS stimulation alone.  The cell death is temporally associated with IL-1beta release, and is consistent with pyronecrosis. In contrast, CD14hi/CD16low cells from healthy subjects only release IL-1beta after both LPS and ATP stimulation and are relatively resistant to cell death.  IL-1beta release is partially inhibited in NOMID cells by caspase-1 inhibitors, and is blocked completely by inhibitors of cathepsin B.  Cathepsin B inhibitors also prevent pyronecrosis.  Similar to cathepsin, STAT3 inhibitors significantly abrogated cell death and IL-1beta release in NOMID cells. STAT3 inhibition also abolished all ATP-dependent IL-1beta release and cell death in monocytes from healthy subjects.  Moreover, shRNA-mediated knockdown of STAT3 in THP-1 cells completely prevented ATP dependent IL-1b release and cell death. We confirm that STAT3 associates with mitochondria, and that inhibition of STAT3 but not cathepsin B, prevents mitochondrial damage suggesting that mitochondrial STAT3 activation may be upstream of cathepsin B activation.

Conclusion: These results identify the predominant IL-1beta-producing cell population in the peripheral blood of NOMID patients and healthy contorls, and identify a novel role for STAT3 in mediating NLRP3 effects on pyronecrosis and IL-1beta release. We suggest that cell death may contribute to IL-1beta release.


Disclosure:

J. H. Edwan,
None;

T. M. Tran,
None;

M. Abu-Asab,
None;

R. T. Goldbach-Mansky,
None;

R. A. Colbert,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stat3-plays-a-central-role-in-nlrp3-inflammasome-mediated-il-1%ce%b2-production-and-pyronecrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology